267.82

0.85% -2.1274

Alnylam Pharmaceuticals Inc (ALNY)

Overview News Price History Option Chain Financials Why ALNY Down? Discussions Forecast

Alnylam Pharmaceuticals Inc stock is traded at $267.82, with a volume of 301.45K. It is down -0.85% in the last 24 hours and down -0.13% over the past month. Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Previous Close:

$269.95

Open:

$268.47

24h Volume:

301.45K

Relative Volume:

0.38

Market Cap:

$34.29B

Revenue:

$2.09B

Net Income/Loss:

$-332.26M

P/E Ratio:

-64.69

EPS:

-4.14

Net Cash Flow:

$16.06M

1W Performance:

-5.99%

1M Performance:

-0.13%

6M Performance:

+75.70%

1Y Performance:

+59.93%

1-Day Range:

$264.55

$268.89

1-Week Range:

$263.65

$287.87

52-Week Range:

$141.97

$304.39

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Name

Alnylam Pharmaceuticals Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

(617) 551-8200

Address

675 WEST KENDALL STREET, CAMBRIDGE, MA

Employee

2,100

Twitter

@alnylam

Next Earnings Date

2024-10-31

Latest SEC Filings

ALNY's Discussions on Twitter

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-16-24	Upgrade	Goldman	Neutral → Buy
Feb-16-24	Downgrade	Goldman	Buy → Neutral
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-08-23	Initiated	Wells Fargo	Equal Weight
Oct-11-23	Downgrade	Oppenheimer	Outperform → Perform
Sep-29-23	Initiated	Raymond James	Outperform
May-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform
Apr-26-23	Initiated	SMBC Nikko	Neutral
Mar-21-23	Initiated	Bernstein	Outperform
Jan-18-23	Initiated	Canaccord Genuity	Buy
Sep-09-22	Resumed	Morgan Stanley	Equal-Weight
Jul-13-22	Initiated	Cantor Fitzgerald	Neutral
Jun-27-22	Downgrade	Guggenheim	Buy → Neutral
Jun-07-22	Initiated	William Blair	Outperform
Apr-25-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-01-22	Initiated	Citigroup	Buy
Feb-03-22	Upgrade	Guggenheim	Neutral → Buy
Jan-03-22	Upgrade	Piper Sandler	Neutral → Overweight
Nov-22-21	Upgrade	Goldman	Neutral → Buy
Nov-22-21	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Nov-01-21	Upgrade	Oppenheimer	Perform → Outperform
Oct-04-21	Upgrade	UBS	Neutral → Buy
Aug-04-21	Downgrade	Piper Sandler	Overweight → Neutral
Feb-22-21	Downgrade	Guggenheim	Buy → Neutral
Feb-12-21	Downgrade	Citigroup	Buy → Neutral
Feb-12-21	Reiterated	H.C. Wainwright	Buy
Jan-25-21	Downgrade	BMO Capital Markets	Outperform → Market Perform
Sep-30-20	Resumed	Berenberg	Hold
Sep-08-20	Initiated	Citigroup	Buy
Aug-11-20	Downgrade	Oppenheimer	Outperform → Perform
May-13-20	Initiated	RBC Capital Mkts	Sector Perform
May-07-20	Downgrade	JP Morgan	Overweight → Neutral
Apr-24-20	Resumed	Evercore ISI	Outperform
Mar-19-20	Initiated	Berenberg	Buy
Dec-19-19	Reiterated	Chardan Capital Markets	Buy
Nov-20-19	Initiated	Oppenheimer	Outperform
Nov-13-19	Initiated	BofA/Merrill	Buy
May-23-19	Resumed	Goldman	Neutral
Apr-12-19	Initiated	Evercore ISI	Outperform
Mar-06-19	Upgrade	Evercore ISI	In-line → Outperform
Mar-05-19	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-23-19	Initiated	UBS	Neutral
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight
Aug-13-18	Reiterated	Stifel	Buy
Aug-07-18	Upgrade	Stifel	Hold → Buy
May-04-18	Reiterated	Stifel	Hold
Mar-28-18	Initiated	Evercore ISI	In-line

View All

Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News

08:34 AM

Alnylam's SWOT analysis: biotech stock poised for growth in ATTR-CM market - Investing.com

08:34 AM

08:03 AM

Alnylam launches Phase 1 trial of ALN-HTT02 for Huntington’s - Huntington's Disease News

08:03 AM

03:13 AM

Raymond James & Associates Has $3.01 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat

03:13 AM

Nov 04, 2024

Alnylam Pharmaceuticals, Inc. Promotes Cynthia Clayton to Vice President of Investor Relations and Corporate Communications - Marketscreener.com

Nov 04, 2024

Alnylam shares remain Buy-rated at H.C. Wainwright, target held steady amid ATTR-CM updates - Investing.com UK

Nov 04, 2024

Alnylam Pharmaceuticals' (ALNY) Buy Rating Reiterated at HC Wainwright - MarketBeat

Nov 04, 2024

Alnylam to Webcast Presentations at Upcoming November Investor Conferences - StockTitan

Nov 04, 2024

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Wealth Enhancement Advisory Services LLC - MarketBeat

Nov 04, 2024

Nov 03, 2024

Alnylam Pharmaceuticals (NASDAQ:ALNY) Announces Quarterly Earnings Results - MarketBeat

Nov 03, 2024

Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down - MSN

Nov 03, 2024

Nov 02, 2024

Silvant Capital Management LLC Has $4.45 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat

Nov 02, 2024

Nov 01, 2024

Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) - Benzinga

Nov 01, 2024

Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - MarketBeat

Nov 01, 2024

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2024 Earnings Call Transcript - MSN

Nov 01, 2024

Needham & Company LLC Reiterates "Buy" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat

Nov 01, 2024

Alnylam Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St

Nov 01, 2024

AustralianSuper Pty Ltd Invests $1 Million in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat

Nov 01, 2024